MAPK3 and type 2 diabetes mellitus: In summary, although our findings indicate that the JAK/STAT and MAPK/ERK1,2 signalling pathways are viable targets for reducing mROS production in HSVSMCs from both non-diabetic and T2DM patients, we acknowledge that more investigations will be required to further elucidate these initial findings.